Bispecific antibodies are top of mind at this year’s ASH meeting as they start to venture into new targets and indications in the clinic. On the latest edition of the BioCentury This Week podcast,...

With 11 days to go before liso-cel’s PDUFA date, FDA has yet to inspect one of two cell therapy facilities where the Bristol Myers Squibb CAR T is being manufactured, signaling a possible delay...

AAV gene editing therapy for Angelman syndromeUniversity of North Carolina at Chapel Hill scientists have created a CRISPR gene therapy for Angelman syndrome that ameliorated motor function deficits in a mouse model of the maternally...

Since its 2015 launch, Triumvira has changed CEOs once, developed a third iteration of its engineered T cell therapeutics platform, and deprioritized a former lead program for blood cancer after it reached the IND stage. Now, the...

A discovery collaboration between Repare and BMS is the former’s first time deploying its platform outside its own pipeline, and the latter’s biggest move yet in synthetic lethality. Repare Therapeutics Inc. announced Tuesday it will...

BioNTech added both a new neoantigen program and a Boston-based operations hub on Thursday through the acquisition of Neon -- a deal for pennies on the dollar. The all-stock transaction will see BioNTech SE (NASDAQ:BNTX)...

Adaptimmune continued its run of J.P. Morgan news Tuesday, announcing a discovery partnership with Japanese pharma Astellas to develop allogeneic T cell therapies for cancer. The announcement follows a 200% gain for Adaptimmune Therapeutics plc...

Standing out at this year's ASH meeting is a pair of growing threats to first-generation CAR T cell therapies: bispecific antibodies and allogeneic cell therapies. Gone are the days when autologous CAR Ts were the...

Lykera joins a growing wave of companies targeting the tumor stroma, but it is taking a different approach with a portfolio of first-in-class mAbs against S100 proteins implicated in driving metastases. Its lead programs are...